Cargando…
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
BACKGROUND: Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion within the huntingtin gene. Mutant huntingtin protein misfolds and accumulates within neurons where it mediates its toxic effects. Promoting mutant huntingtin clearance by activati...
Autores principales: | Fox, Jonathan H, Connor, Teal, Chopra, Vanita, Dorsey, Kate, Kama, Jibrin A, Bleckmann, Dorothee, Betschart, Claudia, Hoyer, Daniel, Frentzel, Stefan, DiFiglia, Marian, Paganetti, Paolo, Hersch, Steven M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908080/ https://www.ncbi.nlm.nih.gov/pubmed/20569486 http://dx.doi.org/10.1186/1750-1326-5-26 |
Ejemplares similares
-
Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors
por: Kegel, Kimberly B, et al.
Publicado: (2010) -
Mechanisms of Copper Ion Mediated Huntington's Disease Progression
por: Fox, Jonathan H., et al.
Publicado: (2007) -
Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington’s Disease
por: Narayanan, K. Lakshmi, et al.
Publicado: (2015) -
Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease
por: Moscovitch-Lopatin, Miriam, et al.
Publicado: (2010) -
Rac1 Activity Is Modulated by Huntingtin and Dysregulated in Models of Huntington’s Disease
por: Tousley, Adelaide, et al.
Publicado: (2019)